Bristol Looking For Deals, Immuno-Oncology And Otherwise
This article was originally published in The Pink Sheet Daily
Executive Summary
Business development is a top priority for Bristol, management said during the company’s second quarter earnings call, and the focus is on expanding in immuno-oncology portfolio and other core therapeutic areas.
You may also be interested in...
Bristol/Medarex: A Transformational Acquisition Rooted In Collaboration
Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.
Emerging Markets Earnings Roundup: Bristol Myers Squibb (Part 6)
Bristol Myers Squibb saw some turbulence for Baraclude sales in China and Japan, but noted Yervoy sales lifted and the company has high hopes for a deal with Ono and its Opdivo oncology treatment.
Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.